Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • RADIATION-THERAPY  (9)
  • 1
    Keywords: radiotherapy ; TUMORS ; RADIATION-THERAPY ; chemotherapy ; SQUAMOUS-CELL CARCINOMA ; INTENSITY-MODULATED RADIOTHERAPY ; CISPLATIN ; IMRT ; reirradiation ; NASOPHARYNGEAL CARCINOMA ; ONCOLOGY-GROUP ; head and neck cancer ; XEROSTOMIA ; Recurrent head and neck cancer ; late toxicity ; UNRESECTABLE HEAD
    Abstract: Background In this retrospective investigation we analyzed outcome and toxicity after intensity-modulated reirradiation of recurrent head and neck cancer. Results Median overall survival was 17 months, and the 1- and 2-year overall survival rates were 63% and 34%. The 1- and 2-year local control rates were 57% and 53%. Distant spread occurred in 34%, and reirradiation induced considerable late toxicity in 21% of the patients. Thirty-two percent showed increased xerostomia after reirradiation. The risk for xerostomia was significantly higher for cumulative mean doses of greater-than-or-equal 45 Gy to parotid glands. Considering median cumulative maximum doses of 53 Gy to the spinal cord and 63 Gy to the brainstem, no late toxicities were observed. Conclusions Reirradiation with intensity-modulated radiotherapy in recurrent head and neck cancer is feasible with acceptable toxicity and yields encouraging rates of local control and overall survival.
    Type of Publication: Journal article published
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CANCER ; IRRADIATION ; radiotherapy ; SURVIVAL ; Germany ; LUNG ; THERAPY ; TOXICITY ; lung cancer ; LUNG-CANCER ; SURGERY ; radiation ; PATIENT ; CYCLE ; treatment ; antibodies ; antibody ; STAGE ; TRIAL ; RADIATION-THERAPY ; RATES ; metastases ; chemotherapy ; RESECTION ; CARCINOMAS ; OVEREXPRESSION ; IMRT ; FEASIBILITY ; PHASE-II ; NECK-CANCER ; SUBSET ; CONCURRENT ; ADVANCED HEAD ; INFUSION ; PHASE ; REMISSION ; prospective ; NSCLC ; C225 ; FACTOR RECEPTOR BLOCKADE ; stage III ; surgical resection
    Abstract: Background: Even today, treatment of Stage III NSCLC still poses a serious challenge. So far, surgical resection is the treatment of choice. Patients whose tumour is not resectable or who are unfit to undergo surgery are usually referred to a combined radio-chemotherapy. However, combined radio-chemotherapeutic treatment is also associated with sometimes marked side effects but has been shown to be more efficient than radiation therapy alone. Nevertheless, there is a significant subset of patients whose overall condition does not permit administration of chemotherapy in a combined-modality treatment. It could be demonstrated though, that NSCLCs often exhibit over-expression of EGF-receptors hence providing an excellent target for the monoclonal EGFR-antagonist cetuximab (Erbitux(R)) which has already been shown to be effective in colorectal as well as head-and-neck tumours with comparatively mild side-effects. Methods/design: The NEAR trial is a prospective phase II feasibility study combining a monoclonal EGF-receptor antibody with loco-regional irradiation in patients with stage III NSCLC. This trial aims at testing the combination's efficacy and rate of development of distant metastases with an accrual of 30 patients. Patients receive weekly infusions of cetuximab (Erbitux(R)) plus loco-regional radiation therapy as intensity-modulated radiation therapy. After conclusion of radiation treatment patients continue to receive weekly cetuximab for 13 more cycles. Discussion: The primary objective of the NEAR trial is to evaluate toxicities and feasibility of the combined treatment with cetuximab (Erbitux(R)) and IMRT loco-regional irradiation. Secondary objectives are remission rates, 3-year-survival and local/systemic progression-free survival
    Type of Publication: Journal article published
    PubMed ID: 16681848
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: CELLS ; radiotherapy ; SURVIVAL ; tumor ; CELL ; Germany ; neoplasms ; THERAPY ; TOXICITY ; FOLLOW-UP ; DISEASE ; TUMORS ; SURGERY ; radiation ; MRI ; PROGRESSION ; CONFORMAL RADIOTHERAPY ; EXPERIENCE ; RADIATION-THERAPY ; AGE ; EFFICACY ; REGION ; HEAD ; NECK ; local control ; ONCOLOGY ; overall survival ; radiation therapy ; MENINGIOMAS ; BONE ; SCAN ; INSTITUTION ; CASE SERIES
    Abstract: Background: Giant cell tumors are rare neoplasms, representing less than 5% of all bone tumors. The vast majority of giant cell tumors occurs in extremity sites and is treated by surgery alone. However, a small percentage occurs in pelvis, spine or skull bones, where complete resection is challenging. Radiation therapy seems to be an option in these patients, despite the lack of a generally accepted dose or fractionation concept. Here we present a series of five cases treated with high dose IMRT. Patients and Methods: From 2000 and 2006 a total of five patients with histologically proven benign giant cell tumors have been treated with IMRT in our institution. Two patients were male, three female, and median age was 30 years (range 20 - 60). The tumor was located in the sacral region in four and in the sphenoid sinus in one patient. All patients had measurable gross disease prior to radiotherapy with a median size of 9 cm. All patients were treated with IMRT to a median total dose of 64 Gy (range 57.6 Gy to 66 Gy) in conventional fractionation. Results: Median follow up was 46 months ranging from 30 to 107 months. Overall survival was 100%. One patient developed local disease progression three months after radiotherapy and needed extensive surgical salvage. The remaining four patients have been locally controlled, resulting in a local control rate of 80%. We found no substantial tumor shrinkage after radiotherapy but in two patients morphological signs of extensive tumor necrosis were present on MRI scans. Decline of pain and/or neurological symptoms were seen in all four locally controlled patients. The patient who needed surgical salvage showed markedly reduced pain but developed functional deficits of bladder, rectum and lower extremity due to surgery. No severe acute or late toxicities attributable to radiation therapy were observed so far. Conclusion: IMRT is a feasible option in giant cells tumors not amendable to complete surgical removal. In our case series local control was achieved in four out of five patients with marked symptom relief in the majority of cases. No severe toxicity was observed
    Type of Publication: Journal article published
    PubMed ID: 20187955
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Keywords: SURVIVAL ; SURGERY ; RADIATION-THERAPY ; SQUAMOUS-CELL CARCINOMA ; adenocarcinoma ; RANDOMIZED-TRIAL ; chemoradiation ; 3D conformal radiotherapy ; NEOADJUVANT CHEMORADIOTHERAPY ; DOSE RADIATION
    Abstract: BACKGROUND: To report our experience with increased dose intensity-modulated radiation and concurrent systemic chemotherapy as definitive treatment of locally advanced esophageal cancer. PATIENTS AND METHODS: We analyzed 27 consecutive patients with histologically proven esophageal cancer, who were treated with increased-dose IMRT as part of their definitive therapy. The majority of patients had T3/4 and/or N1 disease (93%). Squamous cell carcinoma was the dominating histology (81%). IMRT was delivered in step-and-shoot technique in all patients using an integrated boost concept. The boost volume was covered with total doses of 56-60 Gy (single dose 2-2.14 Gy), while regional nodal regions received 50.4 Gy (single dose 1.8 Gy) in 28 fractions. Concurrent systemic therapy was scheduled in all patients and administered in 26 (96%). 17 patients received additional adjuvant systemic therapy. Loco-regional control, progression-free and overall survival as well as acute and late toxicities were retrospectively analyzed. In addition, quality of life was prospectively assessed according to the EORTC QLQs (QLQ-OG25, QLQ-H&N35 and QLQ-C30). RESULTS: Radiotherapy was completed as planned in all but one patient (96%), and 21 patients received more than 80% of the planned concurrent systemic therapy. We observed ten locoregional failures, transferring into actuarial 1-, 2- and 3-year-locoregional control rates of 77%, 65% and 48%. Seven patients developed distant metastases, mainly to the lung (71%). The actuarial 1-, 2- and 3-year-disease free survival rates were 58%, 48% and 36%, and overall survival rates were 82%, 61% and 56%. The concept was well tolerated, both in the clinical objective examination and also according to the subjective answers to the QLQ questionnaire. 14 patients (52%) suffered from at least one acute CTC grade 3/4 toxicity, mostly hematological side effects or dysphagia. Severe late toxicities were reported in 6 patients (22%), mostly esophageal strictures and ulcerations. Severe side effects to skin, lung and heart were rare. CONCLUSION: IMRT with concurrent systemic therapy in the definitive treatment of esophageal cancer using an integrated boost concept with doses up to 60 Gy is feasible and yields good results with acceptable acute and late overall toxicity and low side effects to skin, lung and heart.
    Type of Publication: Journal article published
    PubMed ID: 25175056
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    Keywords: carcinoma ; TOXICITY ; RADIATION-THERAPY ; chemotherapy ; SQUAMOUS-CELL CARCINOMA ; INTENSITY-MODULATED RADIOTHERAPY ; CISPLATIN ; IMRT ; reirradiation ; NASOPHARYNGEAL CARCINOMA ; ONCOLOGY-GROUP ; PHASE-II ; cetuximab ; PLUS CETUXIMAB ; Recurrent head and neck cancer ; SALVAGE SURGERY
    Abstract: Purpose: In this retrospective investigation, the outcome and toxicity after reirradiation with concurrent cetuximab immunotherapy of recurrent head and neck cancer (HNC) in patients who had contraindications to platinum-based chemotherapy were analyzed. Material and Methods: Ten patients with locally advanced recurrent HNC were retrospectively evaluated. In 9 cases, histology was squamous cell carcinoma, in one case adenoid cystic carcinoma. External beam radiotherapy was part of the initial treatment in all cases. Reirradiation was carried out using step-and-shoot intensity-modulated radiotherapy (IMRT) with a median dose of 50.4 Gy. Cetuximab was applied as loading dose (400 mg/m(2)) 1 week prior to reirradiation and then weekly concurrently with radiotherapy (250 mg/m(2)). Results: The median overall survival time after initiation of reirradiation was 7 months; the 1-year overall survival (OS) rate was 40%. Local failure was found in 3 patients, resulting in a 1-year local control (LC) rate of 61%. The 1-year locoregional control (LRC) rate was 44%, while the 1-year distant metastasis-free survival (DMFS) was 75%. Acute hematological toxicity was not observed in the group. Severe acute toxicity included one fatal infield arterial bleeding and one flap necrosis. Severe late toxicities were noted in 2 patients: fibrosis of the temporomandibular joint in 1 patient and stenosis of the cervical esophagus in another. Conclusions: IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent HNC is feasible with acceptable acute toxicity. Further investigations are necessary to determine the clinical role of this therapy concept
    Type of Publication: Journal article published
    PubMed ID: 21234529
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    Keywords: PATIENT ; radiation ; Germany ; THERAPY ; imaging ; CANCER ; RADIATION-THERAPY ; Jun ; pancreatic cancer ; RECURRENT ; ONCOLOGY ; PANCREATIC-CANCER ; radiation therapy
    Type of Publication: Meeting abstract published
    Signatur Availability
    BibTip Others were also interested in ...
  • 7
    Keywords: RESECTION ; RADIATION-THERAPY ; radiation ; THERAPY
    Type of Publication: Meeting abstract published
    Signatur Availability
    BibTip Others were also interested in ...
  • 8
    Keywords: RECEPTOR ; CANCER ; CANCER CELLS ; CELLS ; GROWTH ; GROWTH-FACTOR ; radiotherapy ; AGENTS ; COMBINATION ; FACTOR RECEPTOR ; Germany ; INHIBITION ; THERAPY ; TOXICITY ; DEATH ; radiation ; TIME ; PATIENT ; MECHANISM ; prognosis ; GROWTH-FACTOR RECEPTOR ; TRIAL ; IDENTIFICATION ; LESIONS ; PROGRESSION ; RADIATION-THERAPY ; resistance ; NUMBER ; WOMEN ; CLINICAL-TRIALS ; MEN ; chemotherapy ; CANCER-CELLS ; CARCINOMA-CELLS ; RECRUITMENT ; STRATEGIES ; SAFETY ; adenocarcinoma ; TARGETS ; QUESTIONNAIRE ; pancreatic cancer ; IMRT ; EPIDERMAL-GROWTH-FACTOR ; PHASE-II ; AGENT ; targeting ; molecular ; GEMCITABINE ; pancreas ; RE ; PANCREATIC-CANCER ; DETERMINANTS ; targeted ; PROTOCOL ; LIFE ; intensity ; QUALITY-OF-LIFE ; quality of life ; radiation therapy ; INTERVAL ; PHASE ; NEED ; EUROPEAN-ORGANIZATION ; phase II ; Molecular targets ; ADJUVANT COMBINED RADIATION ; COMBINED-MODALITY THERAPY ; CURATIVE RESECTION
    Abstract: Background: Pancreatic cancer is the fourth commonest cause of death from cancer in men and women. Advantages in surgical techniques, radiation therapy techniques, chemotherapeutic regimes, and different combined-modality approaches have yielded only a modest impact on the prognosis of patients with pancreatic cancer. Thus there is clearly a need for additional strategies. One approach involves using the identification of a number of molecular targets that may be responsible for the resistance of cancer cells to radiation or to other cytotoxic agents. As such, these molecular determinants may serve as targets for augmentation of the radiotherapy or chemotherapy response. Of these, the epidermal growth factor receptor ( EGFR) has been a molecular target of considerable interest and investigation, and there has been a tremendous surge of interest in pursuing targeted therapy of cancers via inhibition of the EGFR. Methods/design: The PARC study is designed as an open, controlled, prospective, randomized phase II trial. Patients in study arm A will be treated with chemoradiation using intensity modulated radiation therapy (IMRT) combined with gemcitabine and simultaneous cetuximab infusions. After chemoradiation the patients receive gemcitabine infusions weekly over 4 weeks. Patients in study arm B will be treated with chemoradiation using intensity modulated radiation therapy ( IMRT) combined with gemcitabine and simultaneous cetuximab infusions. After chemoradiation the patients receive gemcitabine weekly over 4 weeks and cetuximab infusions over 12 weeks. A total of 66 patients with locally advanced adenocarcinoma of the pancreas will be enrolled. An interim analysis for patient safety reasons will be done one year after start of recruitment. Evaluation of the primary endpoint will be performed two years after the last patient's enrolment. Discussion: The primary objective of this study is to evaluate the feasibility and the toxicity profile of trimodal therapy in pancreatic adenocarcinoma with chemoradiation therapy with gemcitabine and intensity modulated radiation therapy (IMRT) and EGFR-targeted therapy using cetuximab and to compare between two different methods of cetuximab treatment schedules ( concomitant versus concomitant and sequential cetuximab treatment). Secondary objectives are to determine the role and the mechanism of cetuximab in patient's chemoradiation regimen, the response rate, the potential of this combined modality treatment to concert locally advanced lesions to potentially resectable lesions, the time to progression interval and the quality of life
    Type of Publication: Journal article published
    PubMed ID: 16219105
    Signatur Availability
    BibTip Others were also interested in ...
  • 9
    Keywords: radiotherapy ; SURVIVAL ; Germany ; THERAPY ; CLASSIFICATION ; FOLLOW-UP ; radiation ; TIME ; PATIENT ; SKIN ; T cell ; T-CELL ; STAGE ; LYMPHOMA ; RADIATION-THERAPY ; AGE ; EFFICIENT ; ELECTRON ; FRANCE ; BEAM ; CTCL ; non-hodgkin's lymphoma ; MANAGEMENT ; MYCOSIS-FUNGOIDES ; THERAPIES ; overall survival ; GRADE ; T-CELL LYMPHOMA ; cutaneous T-cell lymphoma ; radiation therapy ; REMISSION ; SYMPTOMS ; mycosis fungoides ; PROGRESSION-FREE SURVIVAL ; response ; non-Hodgkin ; CORRELATE ; COURSES ; EORTC ; total skin radiotherapy ; TSEBT
    Abstract: Our aim was to analyze the effectiveness of palliative total skin electron beam therapy (TSEBT) in the management of advanced cutaneous T-cell non-Hodgkin's lymphoma (CTCL). Eighteen patients (median age 59 Years) with advanced and therapy-refractory CTCL in stages IIB-IV were treated with TSEBT for the first time. The most common histological subtype was Mycosis fungoides (72%). All patients suffered from lymphoma-associated symptoms. Median daily fractions of 1 Gy were administered up to a median total dose of 25 Gy. The median follow-up period. was 11 months. Nine patients (50%) achieved a complete response and seven patients (39%) had a limited response. The actuarial one-Year progression-free survival was 24%. Four patients (22%) had continuing remission over a median period of six months. Lymphoma associated symptoms were improved in 16 patients (89%). The median overall survival after receiving TSEBT was 12 months, resulting in an actuarial one-year overall survival of 48%. Treatment related acute effects (grade 1 or 2) were observed in all patients during radiation therapy. Transient grade 3 epitheliolyses developed in five patients (28%), late skin effects (grade 1 and 2) in 16 patients (89%), and hypohidrosis was seen in six patients (33%). We conclude that TSEBT is a very efficient and tolerable palliative treatment for patients with advanced CTCL
    Type of Publication: Journal article published
    PubMed ID: 18474461
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...